6 Medicare Drug Formularies Dropping Familiar Brands

Medicare drug formularies dropping common prescriptions — Image Source: Shutterstock

For millions of seniors, the first trip to the pharmacy in January is a moment of high anxiety. While you may have kept the same Medicare Part D plan as last year, that does not mean your plan kept the same drugs. In 2026, the “Formulary”—the master list of drugs your insurance agrees to pay for—is undergoing its most radical transformation in a decade. Squeezed by the new financial liabilities of the Inflation Reduction Act, insurers are ruthlessly pruning their lists to shed expensive brand-name medications in favor of cheaper alternatives.

This year, the cuts are not limited to obscure medications; they are hitting household names that have been staples of medicine cabinets for years. If your doctor prescribes one of these famous brands, you may find your claim rejected at the counter, forcing you to pay the full cash price or scramble for a new prescription. Here are the six familiar brand-name drugs that are disappearing from Medicare formularies in 2026 and the economic forces driving their removal.

1. The Asthma Standard (Flovent HFA)

For decades, Flovent has been the gold standard inhaler for managing asthma and COPD. However, in a confusing move for patients, the manufacturer (GSK) actually discontinued the branded version of Flovent, replacing it with an “authorized generic.” While this sounds like a simple swap, many Medicare Part D plans have declined to add the new generic to their formularies immediately or have placed it on a non-preferred tier.

As highlighted by the Asthma and Allergy Foundation of America, this leaves patients in a coverage gap where the brand they know is gone, but the generic substitute is not yet covered by their specific plan. Seniors are often forced to switch to entirely different inhaler brands like Arnuity or Qvar, a transition that requires new doctor visits and potential side effect monitoring.

2. The Arthritis Giant (Humira)

The reign of Humira as the world’s best-selling drug has effectively ended in the Medicare market. With the arrival of multiple FDA-approved biosimilars (such as Hyrimoz, Cyltezo, and Hadlima), Part D plans are rapidly dropping the expensive brand-name Humira from their preferred lists. In 2026, insurers like CVS Health (Caremark) have explicitly removed Humira from major commercial and Medicare formularies in favor of these lower-cost biosimilars.

If you are a rheumatoid arthritis patient who tries to refill a script for branded Humira this month, you will likely face a “Non-Formulary” rejection. You must switch to the plan’s preferred biosimilar—which is clinically equivalent but uses a different injection device—or pay thousands of dollars out of pocket.

3. The Blood Thinner Battle (Eliquis vs. Xarelto)

For years, Medicare plans often covered both of the leading anticoagulants, Eliquis and Xarelto, allowing patients and doctors to choose. In 2026, the pressure of Medicare Price Negotiation has forced plans to pick a side. To secure better rebates, many insurers have signed “exclusive” contracts with just one manufacturer.

This means a plan might cover Xarelto but drop Eliquis entirely (or vice versa). According to KFF analysis of Part D plan formularies, this “winner-take-all” formulary design is becoming the norm. Patients stabilized on the “losing” drug are receiving letters forcing them to switch to the competitor drug for non-medical reasons, a dangerous disruption for those managing stroke risk.

4. The Legacy Insulins (Lantus and Levemir)

While the $35 monthly copay cap for insulin is a huge win for seniors, it comes with a catch: it only applies to the insulins on your plan’s formulary. To maximize profits under this cap, plans are narrowing their lists. Many have dropped “legacy” brand names like Lantus or Levemir in favor of specific biosimilars (like Semglee or Basaglar) or unbranded biologics.

If your plan dropped Lantus, the $35 cap no longer applies to it; you would pay full price. You only get the capped price if you switch to the specific insulin product your plan has chosen. This has created widespread confusion at pharmacy counters, where seniors assume all insulin is capped, only to find out their specific brand is now full price.

5. The “Off-Label” GLP-1s (Ozempic/Mounjaro)

The crackdown on weight loss drugs has reached a fever pitch. While Ozempic and Mounjaro are covered for Type 2 Diabetes, plans are aggressively purging them from formularies for anyone without a strict diabetes diagnosis code. In previous years, doctors could sometimes get these approved for “Pre-Diabetes” or metabolic syndrome.

Insurers are using AI-driven audits to retroactively check patient history. If your medical record does not show a history of A1C levels confirming diabetes, the drug is dropped from your coverage. As noted in recent payer coverage updates, this is technically a “utilization management” drop, but the effect is the same: the drug is no longer covered for you, despite your history of taking it.

6. The Eye Drop Staple (Restasis)

For years, Restasis was the only option for chronic dry eye, commanding a premium price and Tier 3 status. With the release of the generic cyclosporine and the competitor brand Xiidra, Medicare plans are finally cutting the cord on the expensive brand-name Restasis.

Many formularies have moved brand-name Restasis to the “Non-Formulary” or “Exclusion” list, mandating that patients try the generic version first. While the active ingredient is the same, patients often complain that the generic drop mechanism or consistency feels different. Regardless of preference, the brand name is now a luxury item that most Part D plans are no longer willing to subsidize.

Don’t Just Pay—Appeal

If your medication has been dropped, do not automatically reach for your credit card. The first step is to call your doctor and ask if a “Therapeutic Interchange” (switching to the covered alternative) is safe for you. In many cases, the generic or competitor drug works perfectly fine. However, if you have a specific medical reason why you must stay on the dropped brand—such as an allergic reaction to the alternative—you have the right to file a “Formulary Exception Request.” This is a formal appeal asking the plan to cover the drug as a medical necessity. It requires paperwork from your doctor, but if approved, it can lock in your coverage for the rest of the year.

Did your Medicare plan drop your blood thinner or insulin this year? Leave a comment below—let us know which brands are disappearing from your coverage!